Study guide
16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives
Key Takeaways Explain This Topic AI
Time to first cigarette after waking is the single most predictive item on the Fagerstrom Test for Nicotine Dependence, and 30 minutes or less indicates higher dependence.
The 5 A's are Ask, Advise, Assess, Assist and Arrange, while Ask-Advise-Refer is the abbreviated model for settings that cannot deliver counseling directly.
Combining behavioral counseling with pharmacotherapy roughly doubles quit rates compared with either alone.
Counseling effect is dose-dependent: four or more sessions totaling more than 90 minutes of contact produces substantially higher abstinence than brief advice alone.
Opt-out referral models, in which quitline referral is automatic unless the patient declines, produce far higher enrollment than opt-in models.
Last updated: September 2026
16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives
Quick Answer: Assess dependence with the Fagerstrom Test for Nicotine Dependence (FTND) , whose most predictive single item is time to first cigarette ( 30 minutes or less signals higher dependence). Deliver the 5 A's — Ask, Advise, Assess, Assist, Arrange — or, in constrained settings, Ask-Advise-Refer . Counseling plus medication roughly doubles quit rates versus either alone, and counseling is dose-dependent : four or more sessions and more than 90 minutes of total contact substantially outperform brief advice. Opt-out quitline referral dramatically outperforms opt-in.
- 1. Structured Assessment
- The FTND in practice
The six-item FTND yields 0 to 10. Two items carry most of the predictive weight:
Time to first cigarette after waking: within 5 minutes (3 points), 6 to 30 minutes (2), 31 to 60 minutes (1), after 60 minutes (0).
Cigarettes per day: 10 or fewer (0), 11 to 20 (1), 21 to 30 (2), 31 or more (3).
A Heaviness of Smoking Index using only those two items performs nearly as well as the full scale and is what most clinicians actually use. A first cigarette within 30 minutes predicts more severe withdrawal and identifies patients who benefit most from combination NRT or varenicline .
What else to assess
- Domain Question that earns its place
- Quit history "What is the longest you have ever gone without smoking, and what ended it?"
Prior pharmacotherapy "Which medicines have you tried, at what dose, for how long?" — most prior "failures" were underdosed or stopped in week 2
Withdrawal profile Irritability, anxiety, concentration difficulty, appetite, insomnia, depressed mood
Weight concern Especially relevant in women; predicts relapse and is modifiable with counseling and agent choice
Co-occurring conditions Depression, bipolar disorder, schizophrenia, alcohol use disorder — all raise relapse risk and change agent selection
- Household smoking A smoking partner is among the strongest predictors of relapse
- Triggers Coffee, driving, alcohol, breaks at work, phone calls, after meals
- 2. The 5 A's and the Abbreviated Models
- Step Action
- Ask Screen every patient for tobacco use at every visit and document it as a vital sign
- Advise Deliver clear, strong, personalized advice to quit, tied to something the patient cares about
- Assess Determine willingness to attempt a quit in the next 30 days
- Assist Offer medication, counseling, a quit date, and practical strategies
- Arrange Schedule follow-up, ideally within the first week after the quit date when relapse risk peaks
Ask-Advise-Refer (AAR) compresses the model for settings without counseling capacity: screen, advise, and refer to a quitline or tobacco treatment specialist. Ask-Advise-Connect (AAC) goes further by making the referral electronically at the point of care rather than handing over a phone number, and produces substantially higher enrollment.
For the patient not ready to quit — the 5 R's
Relevance, Risks, Rewards, Roadblocks, Repetition. Motivational content delivered at each visit, without a quit-date demand. The APRN's goal at this stage is to move ambivalence, not to extract a commitment.
3. Behavioral Treatment Formats
Format Evidence Practical notes
Brief clinician advice (under 3 minutes) Small but real increase in quit rates; scales to every patient encounter The floor, never the ceiling
Individual counseling Dose-dependent; 4 or more sessions and more than 90 total minutes produce the largest effect Focus on problem solving and social support
Group counseling Comparable to individual Cost-effective; some patients decline group formats
Telephone quitlines Proactive multi-call counseling is effective and free in every US state Opt-out referral raises enrollment several-fold over opt-in
Text-message and app programs Modest independent benefit Useful adjunct between visits
Financial incentives Among the most effective behavioral strategies, including in pregnancy Effects attenuate after incentives end, mirroring contingency management for stimulants
Practical problem-solving content that actually works: identify and rehearse specific trigger responses; remove all tobacco, lighters and ashtrays before the quit date; alter the routines that anchor smoking (change the morning sequence, avoid the smoking route); enlist a household member; and plan for alcohol, which is the most common single precipitant of first-week relapse.
4. Reduce-to-Quit and Cutting Down
For patients unwilling to set a quit date, reduction with NRT support is a legitimate strategy with randomized evidence that it increases later quit attempts and abstinence. The essential counseling caveat is compensatory smoking : when patients cut the number of cigarettes, they inhale more deeply and hold smoke longer, so toxicant exposure falls far less than cigarette count suggests. Frame reduction as a bridge to quitting, never as a durable endpoint.
5. Follow-Up Timing
Relapse risk is highest in the first week after the quit date and remains substantial through three months . Arrange contact within the first week , again at one month , and at three months . At each contact, ask specifically about medication adherence and dose, because premature discontinuation at week 2 — when side effects peak and benefit is not yet obvious — is the most common preventable cause of failure.